A D Hamilton Selected Research

Neoplasms (Cancer)

2/2007	Farnesyltransferase and geranylgeranyltransferase I inhibitors upregulate RhoB expression by HDAC1 dissociation, HAT association and histone acetylation of the RhoB promoter.
2/2003	The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells.
7/2002	The farnesyltransferase inhibitor, FTI-2153, inhibits bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation status.
8/2001	v-Src transformation is mediated through farnesylated proteins.
2/2001	CEP1612, a dipeptidyl proteasome inhibitor, induces p21WAF1 and p27KIP1 expression and apoptosis and inhibits the growth of the human lung adenocarcinoma A-549 in nude mice.
12/2000	Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
12/2000	Design of growth factor antagonists with antiangiogenic and antitumor properties.
12/2000	Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues.
11/2000	Inhibition of farnesyltransferase increases TGFbeta type II receptor expression and enhances the responsiveness of human cancer cells to TGFbeta.
10/2000	Direct tumor lysis by NK cells uses a Ras-independent mitogen-activated protein kinase signal pathway.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

A D Hamilton Research Topics

Disease

14	Neoplasms (Cancer) 02/2007 - 01/2000
3	Lung Neoplasms (Lung Cancer) 07/2002 - 02/2001
1	Brain Neoplasms (Brain Tumor) 02/2007
1	Fibrosarcoma 07/2002
1	Adenocarcinoma of Lung 02/2001
1	Carcinogenesis 12/2000
1	Vaccinia 10/2000
1	Systemic Scleroderma (Systemic Sclerosis) 07/2000
1	Liver Cirrhosis (Hepatic Cirrhosis) 01/2000
1	Adenoma (Adenomas) 01/2000

Drug/Important Bio-Agent (IBA)

9	Farnesyltranstransferase (Farnesyltransferase)IBA 02/2007 - 01/2000
4	FTI 277IBA 02/2003 - 01/2000
4	TransferasesIBA 02/2003 - 07/2000
3	geranylgeranyltransferase type-I (protein geranylgeranyltransferase)IBA 02/2007 - 12/2000
2	Antineoplastic Agents (Antineoplastics)IBA 02/2007 - 12/2000
2	GFB 111IBA 12/2000 - 10/2000
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 12/2000 - 01/2000
2	Proteins (Proteins, Gene)FDA Link 12/2000 - 01/2000
1	Histones (Histone)IBA 02/2007
1	DAPIIBA 07/2002
1	DNA (Deoxyribonucleic Acid)IBA 07/2002
1	Oncogene Proteins (Oncogene Protein)IBA 08/2001
1	Uridine Triphosphate (UTP)IBA 02/2001
1	CEP 1612IBA 02/2001
1	Proteasome InhibitorsIBA 02/2001
1	DNA Nucleotidylexotransferase (Terminal Deoxynucleotidyl Transferase)IBA 02/2001
1	LipidsIBA 12/2000
1	ras ProteinsIBA 12/2000
1	Transforming Growth Factor beta (TGF-beta)IBA 11/2000
1	Platelet-Derived Growth FactorIBA 10/2000
1	Interleukin-2 (IL2)IBA 10/2000
1	Mitogen-Activated Protein KinasesIBA 10/2000
1	Collagen Type I (Type I Collagen)IBA 07/2000
1	CollagenIBA 07/2000
1	4- (N- methyl- N- nitrosamino)- 1- (3- pyridyl)- 1- butanoneIBA 01/2000
1	Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA 01/2000
1	Phosphotransferases (Kinase)IBA 01/2000
1	Codon (Codons)IBA 01/2000
1	PeptidomimeticsIBA 01/2000
1	Tyrosine (L-Tyrosine)FDA Link 01/2000
1	FTI 276IBA 01/2000
1	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2000

Therapy/Procedure

3	Therapeutics 12/2000 - 12/2000
1	Ligation 10/2000